Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.

What Was Tested

The paper reports a study of Angiotensin-Converting Enzyme Inhibitors, published as a controlled clinical trial.

In the present study, the clinical effects of candesartan were investigated and compared with ACE inhibitors in patients with stage 2 or 3A diabetic nephropathy, mainly with respect to the effects on the urinary excretion of albumin and type IV collagen.

Who Took Part

According to the abstract, 23 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Forty-nine patients (26 males/23 females) with diabetic nephropathy (stage 2 or 3A), including normotensive patients, were the study subjects.

The patients were treated with either an ACE inhibitor (23 patients) or candesartan (26 patients) for 11 +/- 3 months.

How the Study Was Run

The urinary excretion of albumin and urinary type IV collagen was measured.

What Was Measured

The subject headings attached to it are Albuminuria, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds and Cohort Studies.

What This Means in Plain Language

This is a controlled clinical trial of Angiotensin-Converting Enzyme Inhibitors in 23 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Clinical and experimental nephrology), a journal based in Japan.

More context: all human trials.